Welcome Logout

COVID-19 Clinical Trials

TRICARE's temporary coverage of National Institute of Allergy and Infectious Disease (NIAID)-sponsored COVID-19 clinical trials ended on April 10, 2023. Eligible beneficiaries who enrolled in a covered trial on or before April 10, 2023, will continue to have their care covered through the end of the trial so long as TRICARE requirements are met.

Providers must notify HNFS of patients’ COVID-19 clinical trial participation via fax at 1-844-818-9289. Include any supporting documentation, the National Clinical Trial (NCT) number and a local point of contact. For additional questions, call our Case/Care Management Line at 1-844-524-3578, option 5.

Coverage included:

  • Medical care and testing required to determine eligibility, including the evaluation for eligibility at the institution conducting the NIAID-sponsor trial.
  • Medical care required as a result of participation in the study, including necessary follow-up care and testing that takes place after the period of active treatment on protocol is completed. This includes all approved pharmaceutical drugs (except for the NIAID-funded investigational agents) and all inpatient and outpatient care, diagnostic, laboratory, rehabilitation, and home health services not otherwise reimbursed under a NIAID grant program.

Beneficiaries must follow authorization requirements based on his/her TRICARE plan and the type of service they are receiving under the trial. The institutional and individual providers must be TRICARE-authorized and treatments must be NIAID-sponsored Phase I, II, III, and IV protocols.

The type of service or setting where the services are provided will determine costs.

Eligible clinical trials can be found on the U.S. National Library of Medicine Database at ClinicalTrials.gov and the NIAID website at www.niaid.nih.gov.